GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+1.64 (+1.48%)

Growth Price

Overvalued by 13.43%

Stability Price

Overvalued by 65.67%

Company Metrics

  • 12.79 P/E
  • 5.91 P/S
  • 9.5 P/B
  • 8.77 EPS
  • 43.15% Cash ROIC
  • 1.76 Cash Ratio
  • 1.72 / 1.5% Dividend
  • 10.83M Avg. Vol.
  • 164.86B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Earnings Reaction History: Gilead Sciences Inc., 55.6% Follow-Through ...
Nasdaq - Oct 29, 2014
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc. Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly ...
Gilead Sciences Inc. Posts Q2 Results, Able to Beat Earnings, Revenue Estimates - 10 hours ago
Based in Foster City, California, Gilead Sciences Inc. (GILD - Analyst Report) is a major player in the healthcare industry.
Gilead Sciences, Inc. (GILD) HCV Prescriptions And Impact On Earnings - Bidness ETC
Gilead Sciences Earnings Preview (GILD) - Seeking Alpha
Notable Earnings: Twitter, Inc. (TWTR), Gilead Sciences (GILD), Black Box ...
Wall Street Pit - 9 hours ago
Twitter, Inc. (TWTR) reported second quarter EPS of $0.07 after the closing bell Tuesday, compared to the consensus estimate of $0.04.
What to Expect From Gilead Sciences Inc.'s Q2 Results
Motley Fool - Jul 24, 2015
Big biotech Gilead Sciences (NASDAQ:GILD) announces its second-quarter results after the market closes on Tuesday, July 28.
Gilead Sciences, Inc.'s (GILD) Latest Plan For HCV Drugs - Bidness ETC
Gilead Sciences' Next Big Move May Not Be What You're Thinking - Fox Business
Tuesday's After-Hours Movers: Twitter, Gilead, Yelp And Buffalo Wild Wings
Benzinga - 10 hours ago
Gilead Sciences, Inc. (NASDAQ: GILD) also delivered strong second quarter results. Earnings came in at $3.15 per share on sales of $8.244 billion, well above the Street's consensus estimate of $2.64 per share and $7.36 billion.
Twitter soars on strong results; Yelp tanks - MarketWatch
BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead
24/7 Wall St. - Jul 26, 2015
Gilead Sciences Inc. (NASDAQ: GILD) is due to report on Tuesday afternoon and comes into its earnings week up 20% so far in 2015 and up 25% versus a year ago.
3 Biotechs Making Waves: MRK, PFE, and GILD - Schaeffers Research (blog)
A Week for BioPharma Earnings - Merck & Co. Inc. (NYSE:MRK) in Focus -
Looking Ahead of Wall Street: Facebook Inc (FB), Gilead Sciences, Inc. (GILD ...
Smarter Analyst - Jul 26, 2015
Wall Street is in the thick of earnings season with Facebook Inc (NASDAQ:FB), Gilead Sciences, Inc. (NASDAQ:GILD), Twitter Inc (NYSE:TWTR), and LinkedIn Corp (NYSE:LNKD) all scheduled to report earnings this week.
Options Strategist Discusses Activity In Gilead And Wynn Ahead Of Earnings
Benzinga - 10 hours ago
Benzinga spoke with TD Ameritrade Chief Strategist JJ Kinahan on Tuesday. He discussed options activity ahead of earnings in Gilead Sciences, Inc. (NASDAQ: GILD) and Wynn Resorts, Limited (NASDAQ: WYNN), which are reporting financial results after ...
Active Stocks Under Review: Gilead Sciences Inc. (NASDAQ:GILD), Huntington ...
wsnewspublishers - 20 hours ago
Gilead Sciences declared the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President and General Counsel.
Is Gilead A Buy Pre Earnings? (GILD)
Seeking Alpha - Jul 27, 2015
Disclosure: I am/we are long GILD. (More...)I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha).